Warhound Launch: Genetically Engineered Military Dogs Set for 2027

Warhound has emerged from stealth mode with a bold mission to revolutionize military working dogs. The company secured $200 million in funding from investors including Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a venture firm backed by U.S. intelligence agencies. This substantial investment values the startup at $1.2 billion and signals significant interest in modernizing a critical component of national defense.

The venture was co-conceived by Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Lamm explained that he met Luckey at a conference about a year ago, where Luckey expressed concern over the state of the military’s canine workforce. The two maintained contact, leading Lamm to research the breeding practices of working dogs. He discovered that many dogs fail training due to inherited issues such as poor eyesight, hip dysplasia, or cancer, prompting the idea of genetic enhancement.

Warhound addresses a growing supply problem. More than 80% of the U.S. military’s working dogs are currently imported from Europe, and fewer than half of those imports are fit for service. This reliance on foreign nations highlights a dwindling domestic supply. The company aims to change this dynamic by engineering dogs with specific traits suited for demanding missions, ensuring a reliable and high-performing domestic source for law enforcement and emergency response teams.

The biological process involves taking cell lines from top-performing breeds, specifically the Belgian Malinois and German Shepherd. These cells are stored in a biobank, where the team will edit the genome to enhance performance and longevity. The goal is to remove genes associated with health problems and add those that improve speed, agility, and olfactory senses for tasks like bomb detection. This approach creates a new type of dog designed for specific operational needs.

Anduril plays a crucial role by providing the hardware and software that will equip these animals. The company will supply protective gear such as vests and goggles that offer situational awareness to both the dogs and their handlers. Lamm described the vision as adding technology on top of the dog rather than inside it. For example, bulletproof vests embedded with sensors could send real-time data back to handlers, allowing for better coordination and safety during high-stakes operations.

Luckey serves as a partner in the venture but does not hold equity, according to Lamm. Colossal holds equity in Warhound and supports the initiative by licensing its gene-editing technology. Colossal is already known for its de-extinction efforts, using AI and cloning techniques to work on species like the dodo and the mammoth. This existing infrastructure provides a strong foundation for the new canine project.

The first batch of engineered dogs is expected to be cloned and incubated soon, with births anticipated in early 2027. Viagen, another company owned by Colossal, will handle the cloning process, leveraging its high success rate in endangered species programs. Lamm hopes these dogs will begin service within two years. The company has not yet determined its pricing model but expects to sell to the Department of Defense, police forces, and other first responders.

The project is proceeding under the guidance of the American Humane Society, which is helping to certify the training program. Lamm stated that the company has briefed numerous government groups and that each dog will be trained and managed like any other military working dog. The American Humane Society applauded the collaboration, noting that it is grounded in science and ethics. They look forward to ensuring the animals are treated humanely, with the added benefit that retired dogs can enter the Society’s reunification program to find new homes.